Search

Your search keyword '"Santoro K"' showing total 83 results
Start Over Author "Santoro K"
83 results on '"Santoro K"'

11. Multiplicity dependence of pion, kaon, proton and lambda production in p-Pb collisions at √SNN = 5.02 TeV

Author

B. Abelev bq, J. Adam aj, D. Adamová by, A. M. Adare dv, M. M. Aggarwal cc, G. Aglieri Rinella ag, M. Agnello ci, A. G. Agocs du, A. Agostinelli y, Z. Ahammed dq, N. Ahmad p, A. Ahmad Masoodi p, I. Ahmed n, S. U. Ahn bj, S. A. Ahn bj, I. Aimo cz, S. Aiola dv, M. Ajaz n, A. Akindinov ba, D. Aleksandrov co, B. Alessandro cz, D. Alexandre cq, A. Alici k, A. Alkin c, J. Alme ah, T. Alt al, V. Altini ad, S. Altinpinar q, I. Altsybeev dp, C. Alves Garcia Prado dg, C. Andrei bt, A. Andronic cl, V. Anguelov ch, J. Anielski av, T. Anticˇic ́ cm, F. Antinori cw, P. Antonioli ct, L. Aphecetche da, H. Appelshäuser at, N. Arbor bm, S. Arcelli y, N. Armesto o, R. Arnaldi cz, T. Aronsson dv, I. C. Arsene cl, M. Arslandok at, A. Augustinus ag, R. Averbeck cl, T. C. Awes bz, M. D. Azmi ce, M. Bach al, A. Badalà cv, Y. W. Baek bl, R. Bailhache at, V. Bairathi cg, R. Bala cz, A. Baldisseri m, F. Baltasar Dos Santos Pedrosa ag, J. Bán bb, R. C. Baral bd, R. Barbera z, F. Barile ad, G. G. Barnaföldi du, L. S. Barnby cq, V. Barret bl, J. Bartke dd, M. Basile y, N. Bastid bl, S. Basu dq, B. Bathen av, G. Batigne da, B. Batyunya bi, P. C. Batzing t, C. Baumann at, I. G. Bearden bv, H. Beck at, N. K. Behera ap, I. Belikov aw, F. Bellini y, R. Bellwied di, E. Belmont Moreno bg, G. Bencedi du, S. Beole w, I. Berceanu bt, A. Bercuci bt, Y. Berdnikov ca, D. Berenyi du, A. A. E. Bergognon da, R. A. Bertens az, D. Berzano w, L. Betev ag, A. Bhasin cf, A. K. Bhati cc, J. Bhom dm, L. Bianchi w, N. Bianchi bn, J. Bielcˇík aj, J. Bielcˇíková by, A. Bilandzic bv, S. Bjelogrlic az, F. Blanco i, F. Blanco di, D. Blau co, C. Blume at, F. Bock bp, A. Bogdanov br, H. Bøggild bv, M. Bogolyubsky ax, L. Boldizsár du, M. Bombara ak, J. Book at, H. Borel m, A. Borissov dt, J. Bornschein al, M. Botje bw, E. Botta w, S. Böttger as, P. Braun Munzinger cl, M. Bregant da, T. Breitner as, T. A. Broker at, T. A. Browning cj, M. Broz ai, R. Brun ag, E. Bruna cz, G. E. Bruno ad, D. Budnikov cn, H. Buesching at, S. Bufalino cz, P. Buncic ag, O. Busch ch, Z. Buthelezi bh, D. Caffarri aa, X. Cai f, H. Caines dv, A. Caliva az, E. Calvo Villar cr, V. Canoa Roman j, G. Cara Romeo ct, F. Carena ag, W. Carena ag, F. Carminati ag, A. Casanova Díaz bn, J. Castillo Castellanos m, E. A. R. Casula u, V. Catanescu bt, C. Cavicchioli ag, C. Ceballos Sanchez h, J. Cepila aj, P. Cerello cz, B. Chang dj, S. Chapeland ag, J. L. Charvet m, S. Chattopadhyay dq, S. Chattopadhyay cp, M. Cherney cb, C. Cheshkov do, B. Cheynis do, V. Chibante Barroso ag, D. D. Chinellato di, P. Chochula ag, M. Chojnacki bv, S. Choudhury dq, P. Christakoglou bw, C. H. Christensen bv, P. Christiansen ae, T. Chujo dm, S. U. Chung ck, C. Cicalo cu, L. Cifarelli k, y, F. Cindolo ct, J. Cleymans ce, F. Colamaria ad, D. Colella ad, A. Collu u, M. Colocci y, G. Conesa Balbastre bm, Z. Conesa del Valle ar, M. E. Connors dv, G. Contin v, J. G. Contreras j, T. M. Cormier dt, Y. Corrales Morales w, P. Cortese ac, I. Cortés Maldonado b, M. R. Cosentino bp, F. Costa ag, P. Crochet bl, R. Cruz Albino j, E. Cuautle bf, L. Cunqueiro bn, A. Dainese cw, R. Dang f, A. Danu be, K. Das cp, D. Das cp, I. Das ar, A. Dash dh, S. Dash ap, S. De dq, H. Delagrange da, A. Deloff bs, E. Dénes du, A. Deppman dg, G. O. V. de Barros dg, A. De Caro k, G. de Cataldo cs, J. de Cuveland al, A. De Falco u, D. De Gruttola ab, k, N. De Marco cz, S. De Pasquale ab, R. de Rooij az, M. A. Diaz Corchero i, T. Dietel av, R. Divià ag, D. Di Bari ad, C. Di Giglio ad, S. Di Liberto cx, A. Di Mauro ag, P. Di Nezza bn, Ø. Djuvsland q, A. Dobrin az, T. Dobrowolski bs, B. Dönigus cl, O. Dordic t, A. K. Dubey dq, A. Dubla az, L. Ducroux do, P. Dupieux bl, A. K. Dutta Majumdar cp, G. D. Erasmo ad, D. Elia cs, D. Emschermann av, H. Engel as, B. Erazmus ag, H. A. Erdal ah, D. Eschweiler al, B. Espagnon ar, M. Estienne da, S. Esumi dm, D. Evans cq, S. Evdokimov ax, G. Eyyubova t, D. Fabris cw, J. Faivre bm, D. Falchieri y, A. Fantoni bn, M. Fasel ch, D. Fehlker q, L. Feldkamp av, D. Felea be, A. Feliciello cz, G. Feofilov dp, J. Ferencei by, A. Fernández Téllez b, E. G. Ferreiro o, A. Ferretti w, A. Festanti aa, J. Figiel dd, M. A. S. Figueredo dg, S. Filchagin cn, D. Finogeev ay, F. M. Fionda ad, E. M. Fiore ad, E. Floratos cd, M. Floris ag, S. Foertsch bh, P. Foka cl, S. Fokin co, A. Francescon aa, U. Frankenfeld cl, U. Fuchs ag, C. Furget bm, M. Fusco Girard ab, J. J. Gaardhøje bv, M. Gagliardi w, A. Gago cr, M. Gallio w, D. R. Gangadharan r, P. Ganoti bz, C. Garabatos cl, E. Garcia Solis l, C. Gargiulo ag, I. Garishvili bq, J. Gerhard al, M. Germain da, A. Gheata ag, M. Gheata ag, B. Ghidini ad, P. Ghosh dq, P. Gianotti bn, P. Giubellino ag, E. Gladysz Dziadus dd, P. Glässel ch, L. Goerlich dd, R. Gomez j, P. González Zamora i, S. Gorbunov al, S. Gotovac dc, L. K. Graczykowski ds, R. Grajcarek ch, A. Grelli az, C. Grigoras ag, A. Grigoras ag, V. Grigoriev br, A. Grigoryan a, S. Grigoryan bi, B. Grinyov c, N. Grion cy, J. F. Grosse Oetringhaus ag, J. Y. Grossiord do, R. Grosso ag, F. Guber ay, R. Guernane bm, B. Guerzoni y, M. Guilbaud do, K. Gulbrandsen bv, H. Gulkanyan a, T. Gunji dl, A. Gupta cf, R. Gupta cf, K. H. Khan n, R. Haake av, Ø. Haaland q, C. Hadjidakis ar, M. Haiduc be, H. Hamagaki dl, G. Hamar du, L. D. Hanratty cq, A. Hansen bv, J. W. Harris dv, H. Hartmann al, A. Harton l, D. Hatzifotiadou ct, S. Hayashi dl, A. Hayrapetyan ag, a, S. T. Heckel at, M. Heide av, H. Helstrup ah, A. Herghelegiu bt, G. Herrera Corral j, N. Herrmann ch, B. A. Hess af, K. F. Hetland ah, B. Hicks dv, B. Hippolyte aw, Y. Hori dl, P. Hristov ag, I. Hrˇivnácˇová ar, M. Huang q, T. J. Humanic r, D. Hutter al, D. S. Hwang s, R. Ilkaev cn, I. Ilkiv bs, M. Inaba dm, E. Incani u, G. M. Innocenti w, C. Ionita ag, M. Ippolitov co, M. Irfan p, M. Ivanov cl, V. Ivanov ca, O. Ivanytskyi c, A. Jachołkowski z, P. M. Jacobs bp, C. Jahnke dg, H. J. Jang bj, M. A. Janik ds, P. H. S. Y. Jayarathna di, S. Jena ap, R. T. Jimenez Bustamante bf, P. G. Jones cq, H. Jung am, A. Jusko cq, S. Kalcher al, P. Kalinˇák bb, A. Kalweit ag, J. H. Kang dw, V. Kaplin br, S. Kar dq, A. Karasu Uysal bk, O. Karavichev ay, T. Karavicheva ay, E. Karpechev ay, A. Kazantsev co, U. Kebschull as, R. Keidel dx, B. Ketzer at, M. M. Khan p, P. Khan cp, S. A. Khan dq, A. Khanzadeev ca, Y. Kharlov ax, B. Kileng ah, T. Kim dw, B. Kim dw, D. J. Kim dj, D. W. Kim am, J. S. Kim am, M. Kim am, M. Kim dw, S. Kim s, S. Kirsch al, I. Kisel al, S. Kiselev ba, A. Kisiel ds, G. Kiss du, J. L. Klay e, J. Klein ch, C. Klein Bösing av, A. Kluge ag, M. L. Knichel cl, A. G. Knospe de, C. Kobdaj ag, M. K. Köhler cl, T. Kollegger al, A. Kolojvari dp, V. Kondratiev dp, N. Kondratyeva br, A. Konevskikh ay, V. Kovalenko dp, M. Kowalski dd, S. Kox bm, G. Koyithatta Meethaleveedu ap, J. Kral dj, I. Králik bb, F. Kramer at, A. Kravcˇáková ak, M. Krelina aj, M. Kretz al, M. Krivda bb, F. Krizek aj, by, an, M. Krus aj, E. Kryshen ca, M. Krzewicki cl, V. Kucera by, Y. Kucheriaev co, T. Kugathasan ag, C. Kuhn aw, P. G. Kuijer bw, I. Kulakov at, J. Kumar ap, P. Kurashvili bs, A. B. Kurepin ay, A. Kurepin ay, A. Kuryakin cn, V. Kushpil by, S. Kushpil by, M. J. Kweon ch, Y. Kwon dw, P. Ladrón de Guevara bf, C. Lagana Fernandes dg, I. Lakomov ar, R. Langoy dr, C. Lara as, A. Lardeux da, A. Lattuca w, S. L. La Pointe az, P. La Rocca z, M. Lechman ag, S. C. Lee am, G. R. Lee cq, I. Legrand ag, J. Lehnert at, R. C. Lemmon bx, M. Lenhardt cl, V. Lenti cs, M. Leoncino w, I. León Monzón df, P. Lévai du, S. Li bl, f, J. Lien dr, q, R. Lietava cq, S. Lindal t, V. Lindenstruth al, C. Lippmann cl, M. A. Lisa r, H. M. Ljunggren ae, D. F. Lodato az, P. I. Loenne q, V. R. Loggins dt, V. Loginov br, D. Lohner ch, C. Loizides bp, X. Lopez bl, E. López Torres h, G. Løvhøiden t, X. G. Lu ch, P. Luettig at, M. Lunardon aa, J. Luo f, C. Luzzi ag, R. Ma dv, A. Maevskaya ay, M. Mager ag, D. P. Mahapatra bd, A. Maire ch, M. Malaev ca, I. Maldonado Cervantes bf, L. Malinina bi, 1, D. Mal’Kevich ba, P. Malzacher cl, A. Mamonov cn, L. Manceau cz, V. Manko co, F. Manso bl, V. Manzari cs, M. Marchisone bl, w, J. Mareš bc, A. Margotti ct, A. Marín cl, C. Markert de, M. Marquard at, I. Martashvili dk, N. A. Martin cl, P. Martinengo ag, M. I. Martínez b, G. Martínez García da, J. Martin Blanco da, Y. Martynov c, A. Mas da, S. Masciocchi cl, M. Masera w, A. Masoni cu, L. Massacrier da, A. Mastroserio ad, A. Matyja dd, J. Mazer dk, R. Mazumder aq, M. A. Mazzoni cx, F. Meddi x, A. Menchaca Rocha bg, J. Mercado Pérez ch, M. Meres ai, Y. Miake dm, K. Mikhaylov bi, L. Milano ag, J. Milosevic t, 2, A. Mischke az, A. N. Mishra aq, D. Mis ́kowiec cl, C. Mitu be, J. Mlynarz dt, B. Mohanty dq, L. Molnar aw, L. Montaño Zetina j, M. Monteno cz, E. Montes i, M. Morando aa, D. A. Moreira De Godoy dg, S. Moretto aa, A. Morreale dj, A. Morsch ag, V. Muccifora bn, E. Mudnic dc, S. Muhuri dq, M. Mukherjee dq, H. Müller ag, M. G. Munhoz dg, S. Murray bh, L. Musa ag, B. K. Nandi ap, R. Nania ct, E. Nappi cs, C. Nattrass dk, T. K. Nayak dq, S. Nazarenko cn, A. Nedosekin ba, M. Nicassio cl, M. Niculescu ag, B. S. Nielsen bv, S. Nikolaev co, S. Nikulin co, V. Nikulin ca, B. S. Nilsen cb, M. S. Nilsson t, F. Noferini k, P. Nomokonov bi, G. Nooren az, A. Nyanin co, A. Nyatha ap, J. Nystrand q, H. Oeschler ch, S. K. Oh am, 3, S. Oh dv, L. Olah du, J. Oleniacz ds, A. C. Oliveira Da Silva dg, J. Onderwaater cl, C. Oppedisano cz, A. Ortiz Velasquez ae, A. Oskarsson ae, J. Otwinowski cl, K. Oyama ch, Y. Pachmayer ch, M. Pachr aj, P. Pagano ab, G. Paic ́ bf, F. Painke al, C. Pajares o, S. K. Pal dq, A. Palaha cq, A. Palmeri cv, V. Papikyan a, G. S. Pappalardo cv, W. J. Park cl, A. Passfeld av, D. I. Patalakha ax, V. Paticchio cs, B. Paul cp, T. Pawlak ds, T. Peitzmann az, H. Pereira Da Costa m, E. Pereira De Oliveira Filho dg, D. Peresunko co, C. E. Pérez Lara bw, D. Perrino ad, W. Peryt ds, 4, A. Pesci ct, Y. Pestov d, V. Petrácˇek aj, M. Petran aj, M. Petris bt, P. Petrov cq, M. Petrovici bt, C. Petta z, M. Pikna ai, P. Pillot da, O. Pinazza ag, L. Pinsky di, N. Pitz at, D. B. Piyarathna di, M. Planinic dn, M. Płoskon ́ bp, J. Pluta ds, S. Pochybova du, P. L. M. Podesta Lerma df, M. G. Poghosyan ag, B. Polichtchouk ax, A. Pop bt, S. Porteboeuf Houssais bl, V. Pospíšil aj, B. Potukuchi cf, S. K. Prasad dt, R. Preghenella k, F. Prino cz, C. A. Pruneau dt, I. Pshenichnov ay, G. Puddu u, V. Punin cn, J. Putschke dt, H. Qvigstad t, A. Rachevski cy, A. Rademakers ag, J. Rak dj, A. Rakotozafindrabe m, L. Ramello ac, S. Raniwala cg, R. Raniwala cg, S. S. Räsänen an, B. T. Rascanu at, D. Rathee cc, W. Rauch ag, A. W. Rauf n, V. Razazi u, K. F. Read dk, J. S. Real bm, K. Redlich bs, 5, R. J. Reed dv, A. Rehman q, P. Reichelt at, M. Reicher az, F. Reidt ag, R. Renfordt at, A. R. Reolon bn, A. Reshetin ay, F. Rettig al, J. P. Revol ag, K. Reygers ch, L. Riccati cz, R. A. Ricci bo, T. Richert ae, M. Richter t, P. Riedler ag, W. Riegler ag, F. Riggi z, A. Rivetti cz, M. Rodríguez Cahuantzi b, A. Rodriguez Manso bw, K. Røed q, t, E. Rogochaya bi, S. Rohni cf, D. Rohr al, D. Röhrich q, R. Romita bx, F. Ronchetti bn, P. Rosnet bl, S. Rossegger ag, A. Rossi ag, P. Roy cp, C. Roy aw, A. J. Rubio Montero i, R. Russo w, E. Ryabinkin co, A. Rybicki dd, S. Sadovsky ax, K. Šafarˇík ag, R. Sahoo aq, P. K. Sahu bd, J. Saini dq, H. Sakaguchi ao, S. Sakai bp, D. Sakata dm, C. A. Salgado o, J. Salzwedel r, S. Sambyal cf, V. Samsonov ca, X. Sanchez Castro bf, L. Šándor bb, A. Sandoval bg, M. Sano dm, G. Santagati z, R. Santoro k, D. Sarkar dq, E. Scapparone ct, F. Scarlassara aa, R. P. Scharenberg cj, C. Schiaua bt, R. Schicker ch, C. Schmidt cl, H. R. Schmidt af, S. Schuchmann at, J. Schukraft ag, M. Schulc aj, T. Schuster dv, Y. Schutz ag, K. Schwarz cl, K. Schweda cl, G. Scioli y, E. Scomparin cz, R. Scott dk, P. A. Scott cq, G. Segato aa, I. Selyuzhenkov cl, J. Seo ck, S. Serci u, E. Serradilla i, A. Sevcenco be, A. Shabetai da, G. Shabratova bi, R. Shahoyan ag, S. Sharma cf, N. Sharma dk, K. Shigaki ao, K. Shtejer h, Y. Sibiriak co, S. Siddhanta cu, T. Siemiarczuk bs, D. Silvermyr bz, C. Silvestre bm, G. Simatovic dn, R. Singaraju dq, R. Singh cf, S. Singha dq, V. Singhal dq, B. C. Sinha dq, T. Sinha cp, B. Sitar ai, M. Sitta ac, T. B. Skaali t, K. Skjerdal q, R. Smakal aj, N. Smirnov dv, R. J. M. Snellings az, R. Soltz bq, M. Song dw, J. Song ck, C. Soos ag, F. Soramel aa, M. Spacek aj, I. Sputowska dd, M. Spyropoulou Stassinaki cd, B. K. Srivastava cj, J. Stachel ch, I. Stan be, G. Stefanek bs, M. Steinpreis r, E. Stenlund ae, G. Steyn bh, J. H. Stiller ch, D. Stocco da, M. Stolpovskiy ax, P. Strmen ai, A. A. P. Suaide dg, M. A. Subieta Vásquez w, T. Sugitate ao, C. Suire ar, M. Suleymanov n, R. Sultanov ba, M. Šumbera by, T. Susa cm, T. J. M. Symons bp, A. Szanto de Toledo dg, I. Szarka ai, A. Szczepankiewicz ag, M. Szyman ́ ski ds, J. Takahashi dh, M. A. Tangaro ad, J. D. Tapia Takaki ar, A. Tarantola Peloni at, A. Tarazona Martinez ag, A. Tauro ag, G. Tejeda Muñoz b, A. Telesca ag, C. Terrevoli ad, A. Ter Minasyan co, J. Thäder cl, D. Thomas az, R. Tieulent do, A. R. Timmins di, A. Toia cw, H. Torii dl, V. Trubnikov c, W. H. Trzaska dj, T. Tsuji dl, A. Tumkin cn, R. Turrisi cw, T. S. Tveter t, J. Ulery at, K. Ullaland q, J. Ulrich as, A. Uras do, G. M. Urciuoli cx, G. L. Usai u, M. Vajzer by, M. Vala bb, L. Valencia Palomo ar, P. Vande Vyvre ag, L. Vannucci bo, J. W. Van Hoorne ag, M. van Leeuwen az, A. Vargas b, R. Varma ap, M. Vasileiou cd, A. Vasiliev co, V. Vechernin dp, M. Veldhoen az, M. Venaruzzo v, E. Vercellin w, S. Vergara b, R. Vernet g, M. Verweij dt, L. Vickovic dc, G. Viesti aa, J. Viinikainen dj, Z. Vilakazi bh, O. Villalobos Baillie cq, A. Vinogradov co, L. Vinogradov dp, Y. Vinogradov cn, T. Virgili ab, Y. P. Viyogi dq, A. Vodopyanov bi, M. A. Völkl ch, S. Voloshin dt, K. Voloshin ba, G. Volpe ag, B. von Haller ag, I. Vorobyev dp, D. Vranic ag, J. Vrláková ak, B. Vulpescu bl, A. Vyushin cn, B. Wagner q, V. Wagner aj, J. Wagner cl, Y. Wang ch, Y. Wang f, M. Wang f, D. Watanabe dm, K. Watanabe dm, M. Weber di, J. P. Wessels av, U. Westerhoff av, J. Wiechula af, J. Wikne t, M. Wilde av, G. Wilk bs, J. Wilkinson ch, M. C. S. Williams ct, B. Windelband ch, M. Winn ch, C. Xiang f, C. G. Yaldo dt, Y. Yamaguchi dl, H. Yang m, P. Yang f, S. Yang q, S. Yano ao, S. Yasnopolskiy co, J. Yi ck, Z. Yin f, I. K. Yoo ck, I. Yushmanov co, V. Zaccolo bv, C. Zach aj, C. Zampolli ct, S. Zaporozhets bi, A. Zarochentsev dp, P. Závada bc, N. Zaviyalov cn, H. Zbroszczyk ds, P. Zelnicek as, I. S. Zgura be, M. Zhalov ca, F. Zhangf, Y. Zhangf, H. Zhangf, X. Zhangbp, bl, f, D. Zhouf, Y. Zhouaz, F. Zhouf, X. Zhuf, J. Zhuf, H. Zhu f, A. Zichichi k, M. B. Zimmermann av, A. Zimmermann ch, G. Zinovjev c, Y. Zoccarato do, M. Zynovyev c, M. Zyzak, CONTIN, GIACOMO, CAMERINI, Paolo, FRAGIACOMO, ENRICO, LEA, RAMONA, LUPARELLO, GRAZIA, MARGAGLIOTTI, GIACOMO, PIANO, STEFANO, RUI, RINALDO, B., Abelev bq, J., Adam aj, D., Adamová by, A. M., Adare dv, M. M., Aggarwal cc, G., Aglieri Rinella ag, M., Agnello ci, Cz, A. G., Agocs du, A., Agostinelli y, Z., Ahammed dq, N., Ahmad p, A., Ahmad Masoodi p, I., Ahmed n, S. U., Ahn bj, S. A., Ahn bj, I., Aimo cz, Ci, S., Aiola dv, M., Ajaz n, A., Akindinov ba, D., Aleksandrov co, B., Alessandro cz, D., Alexandre cq, A., Alici k, Ct, A., Alkin c, J., Alme ah, T., Alt al, V., Altini ad, S., Altinpinar q, I., Altsybeev dp, C., Alves Garcia Prado dg, C., Andrei bt, A., Andronic cl, V., Anguelov ch, J., Anielski av, T., Anticˇic ́ cm, F., Antinori cw, P., Antonioli ct, L., Aphecetche da, H., Appelshäuser at, N., Arbor bm, S., Arcelli y, N., Armesto o, R., Arnaldi cz, T., Aronsson dv, I. C., Arsene cl, M., Arslandok at, A., Augustinus ag, R., Averbeck cl, T. C., Awes bz, M. D., Azmi ce, M., Bach al, A., Badalà cv, Y. W., Baek bl, Am, R., Bailhache at, V., Bairathi cg, R., Bala cz, Cf, A., Baldisseri m, F., Baltasar Dos Santos Pedrosa ag, J., Bán bb, R. C., Baral bd, R., Barbera z, F., Barile ad, G. G., Barnaföldi du, L. S., Barnby cq, V., Barret bl, J., Bartke dd, M., Basile y, N., Bastid bl, S., Basu dq, B., Bathen av, G., Batigne da, B., Batyunya bi, P. C., Batzing t, C., Baumann at, I. G., Bearden bv, H., Beck at, N. K., Behera ap, I., Belikov aw, F., Bellini y, R., Bellwied di, E., Belmont Moreno bg, G., Bencedi du, S., Beole w, I., Berceanu bt, A., Bercuci bt, Y., Berdnikov ca, D., Berenyi du, A. A. E., Bergognon da, R. A., Bertens az, D., Berzano w, L., Betev ag, A., Bhasin cf, A. K., Bhati cc, J., Bhom dm, L., Bianchi w, N., Bianchi bn, J., Bielcˇík aj, J., Bielcˇíková by, A., Bilandzic bv, S., Bjelogrlic az, F., Blanco i, F., Blanco di, D., Blau co, C., Blume at, F., Bock bp, Ch, A., Bogdanov br, H., Bøggild bv, M., Bogolyubsky ax, L., Boldizsár du, M., Bombara ak, J., Book at, H., Borel m, A., Borissov dt, J., Bornschein al, M., Botje bw, E., Botta w, S., Böttger a, P., Braun Munzinger cl, M., Bregant da, T., Breitner a, T. A., Broker at, T. A., Browning cj, M., Broz ai, R., Brun ag, E., Bruna cz, G. E., Bruno ad, D., Budnikov cn, H., Buesching at, S., Bufalino cz, P., Buncic ag, O., Busch ch, Z., Buthelezi bh, D., Caffarri aa, X., Cai f, H., Caines dv, A., Caliva az, E., Calvo Villar cr, Camerini, Paolo, V., Canoa Roman j, Ag, G., Cara Romeo ct, F., Carena ag, W., Carena ag, F., Carminati ag, A., Casanova Díaz bn, J., Castillo Castellanos m, E. A. R., Casula u, V., Catanescu bt, C., Cavicchioli ag, C., Ceballos Sanchez h, J., Cepila aj, P., Cerello cz, B., Chang dj, S., Chapeland ag, J. L., Charvet m, S., Chattopadhyay dq, S., Chattopadhyay cp, M., Cherney cb, C., Cheshkov do, B., Cheynis do, V., Chibante Barroso ag, D. D., Chinellato di, P., Chochula ag, M., Chojnacki bv, S., Choudhury dq, P., Christakoglou bw, C. H., Christensen bv, P., Christiansen ae, T., Chujo dm, S. U., Chung ck, C., Cicalo cu, L., Cifarelli k, Y, F., Cindolo ct, J., Cleymans ce, F., Colamaria ad, D., Colella ad, A., Collu u, M., Colocci y, G., Conesa Balbastre bm, Z., Conesa del Valle ar, M. E., Connors dv, G., Contin v, J. G., Contreras j, T. M., Cormier dt, Y., Corrales Morales w, P., Cortese ac, I., Cortés Maldonado b, M. R., Cosentino bp, F., Costa ag, P., Crochet bl, R., Cruz Albino j, E., Cuautle bf, L., Cunqueiro bn, A., Dainese cw, R., Dang f, A., Danu be, K., Das cp, D., Das cp, I., Das ar, A., Dash dh, S., Dash ap, S., De dq, H., Delagrange da, A., Deloff b, E., Dénes du, A., Deppman dg, G. O. V., de Barros dg, A., De Caro k, Ab, G., de Cataldo c, J., de Cuveland al, A., De Falco u, D., De Gruttola ab, K, N., De Marco cz, S., De Pasquale ab, R., de Rooij az, M. A., Diaz Corchero i, T., Dietel av, R., Divià ag, D., Di Bari ad, C., Di Giglio ad, S., Di Liberto cx, A., Di Mauro ag, P., Di Nezza bn, Ø., Djuvsland q, A., Dobrin az, Dt, T., Dobrowolski b, B., Dönigus cl, At, O., Dordic t, A. K., Dubey dq, A., Dubla az, L., Ducroux do, P., Dupieux bl, A. K., Dutta Majumdar cp, G. D., Erasmo ad, D., Elia c, D., Emschermann av, H., Engel a, B., Erazmus ag, Da, H. A., Erdal ah, D., Eschweiler al, B., Espagnon ar, M., Estienne da, S., Esumi dm, D., Evans cq, S., Evdokimov ax, G., Eyyubova t, D., Fabris cw, J., Faivre bm, D., Falchieri y, A., Fantoni bn, M., Fasel ch, D., Fehlker q, L., Feldkamp av, D., Felea be, A., Feliciello cz, G., Feofilov dp, J., Ferencei by, A., Fernández Téllez b, E. G., Ferreiro o, A., Ferretti w, A., Festanti aa, J., Figiel dd, M. A. S., Figueredo dg, S., Filchagin cn, D., Finogeev ay, F. M., Fionda ad, E. M., Fiore ad, E., Floratos cd, M., Floris ag, S., Foertsch bh, P., Foka cl, S., Fokin co, Fragiacomo, Enrico, A., Francescon aa, U., Frankenfeld cl, U., Fuchs ag, C., Furget bm, M., Fusco Girard ab, J. J., Gaardhøje bv, M., Gagliardi w, A., Gago cr, M., Gallio w, D. R., Gangadharan r, P., Ganoti bz, C., Garabatos cl, E., Garcia Solis l, C., Gargiulo ag, I., Garishvili bq, J., Gerhard al, M., Germain da, A., Gheata ag, M., Gheata ag, Be, B., Ghidini ad, P., Ghosh dq, P., Gianotti bn, P., Giubellino ag, E., Gladysz Dziadus dd, P., Glässel ch, L., Goerlich dd, R., Gomez j, Df, P., González Zamora i, S., Gorbunov al, S., Gotovac dc, L. K., Graczykowski d, R., Grajcarek ch, A., Grelli az, C., Grigoras ag, A., Grigoras ag, V., Grigoriev br, A., Grigoryan a, S., Grigoryan bi, B., Grinyov c, N., Grion cy, J. F., Grosse Oetringhaus ag, J. Y., Grossiord do, R., Grosso ag, F., Guber ay, R., Guernane bm, B., Guerzoni y, M., Guilbaud do, K., Gulbrandsen bv, H., Gulkanyan a, T., Gunji dl, A., Gupta cf, R., Gupta cf, K. H., Khan n, R., Haake av, Ø., Haaland q, C., Hadjidakis ar, M., Haiduc be, H., Hamagaki dl, G., Hamar du, L. D., Hanratty cq, A., Hansen bv, J. W., Harris dv, H., Hartmann al, A., Harton l, D., Hatzifotiadou ct, S., Hayashi dl, A., Hayrapetyan ag, A, S. T., Heckel at, M., Heide av, H., Helstrup ah, A., Herghelegiu bt, G., Herrera Corral j, N., Herrmann ch, B. A., Hess af, K. F., Hetland ah, B., Hicks dv, B., Hippolyte aw, Y., Hori dl, P., Hristov ag, I., Hrˇivnácˇová ar, M., Huang q, T. J., Humanic r, D., Hutter al, D. S., Hwang, R., Ilkaev cn, I., Ilkiv b, M., Inaba dm, E., Incani u, G. M., Innocenti w, C., Ionita ag, M., Ippolitov co, M., Irfan p, M., Ivanov cl, V., Ivanov ca, O., Ivanytskyi c, A., Jachołkowski z, P. M., Jacobs bp, C., Jahnke dg, H. J., Jang bj, M. A., Janik d, P. H. S. Y., Jayarathna di, S., Jena ap, Di, R. T., Jimenez Bustamante bf, P. G., Jones cq, H., Jung am, A., Jusko cq, S., Kalcher al, P., Kalinˇák bb, A., Kalweit ag, J. H., Kang dw, V., Kaplin br, S., Kar dq, A., Karasu Uysal bk, O., Karavichev ay, T., Karavicheva ay, E., Karpechev ay, A., Kazantsev co, U., Kebschull a, R., Keidel dx, B., Ketzer at, M. M., Khan p, P., Khan cp, S. A., Khan dq, A., Khanzadeev ca, Y., Kharlov ax, B., Kileng ah, T., Kim dw, B., Kim dw, D. J., Kim dj, D. W., Kim am, Bj, J. S., Kim am, M., Kim am, M., Kim dw, S., Kim, S., Kirsch al, I., Kisel al, S., Kiselev ba, A., Kisiel d, G., Kiss du, J. L., Klay e, J., Klein ch, C., Klein Bösing av, A., Kluge ag, M. L., Knichel cl, A. G., Knospe de, C., Kobdaj ag, Db, M. K., Köhler cl, T., Kollegger al, A., Kolojvari dp, V., Kondratiev dp, N., Kondratyeva br, A., Konevskikh ay, V., Kovalenko dp, M., Kowalski dd, S., Kox bm, G., Koyithatta Meethaleveedu ap, J., Kral dj, I., Králik bb, F., Kramer at, A., Kravcˇáková ak, M., Krelina aj, M., Kretz al, M., Krivda bb, Cq, F., Krizek aj, By, An, M., Krus aj, E., Kryshen ca, M., Krzewicki cl, V., Kucera by, Y., Kucheriaev co, T., Kugathasan ag, C., Kuhn aw, P. G., Kuijer bw, I., Kulakov at, J., Kumar ap, P., Kurashvili b, A. B., Kurepin ay, A., Kurepin ay, A., Kuryakin cn, V., Kushpil by, S., Kushpil by, M. J., Kweon ch, Y., Kwon dw, P., Ladrón de Guevara bf, C., Lagana Fernandes dg, I., Lakomov ar, R., Langoy dr, C., Lara a, A., Lardeux da, A., Lattuca w, S. L., La Pointe az, P., La Rocca z, Lea, Ramona, M., Lechman ag, S. C., Lee am, G. R., Lee cq, I., Legrand ag, J., Lehnert at, R. C., Lemmon bx, M., Lenhardt cl, V., Lenti c, M., Leoncino w, I., León Monzón df, P., Lévai du, S., Li bl, F, J., Lien dr, Q, R., Lietava cq, S., Lindal t, V., Lindenstruth al, C., Lippmann cl, M. A., Lisa r, H. M., Ljunggren ae, D. F., Lodato az, P. I., Loenne q, V. R., Loggins dt, V., Loginov br, D., Lohner ch, C., Loizides bp, X., Lopez bl, E., López Torres h, G., Løvhøiden t, X. G., Lu ch, P., Luettig at, M., Lunardon aa, J., Luo f, Luparello, Grazia, C., Luzzi ag, R., Ma dv, A., Maevskaya ay, M., Mager ag, D. P., Mahapatra bd, A., Maire ch, M., Malaev ca, I., Maldonado Cervantes bf, L., Malinina bi, D., Mal’Kevich ba, P., Malzacher cl, A., Mamonov cn, L., Manceau cz, V., Manko co, F., Manso bl, V., Manzari c, M., Marchisone bl, W, J., Mareš bc, Margagliotti, Giacomo, A., Margotti ct, A., Marín cl, C., Markert de, M., Marquard at, I., Martashvili dk, N. A., Martin cl, P., Martinengo ag, M. I., Martínez b, G., Martínez García da, J., Martin Blanco da, Y., Martynov c, A., Mas da, S., Masciocchi cl, M., Masera w, A., Masoni cu, L., Massacrier da, A., Mastroserio ad, A., Matyja dd, J., Mazer dk, R., Mazumder aq, M. A., Mazzoni cx, F., Meddi x, A., Menchaca Rocha bg, J., Mercado Pérez ch, M., Meres ai, Y., Miake dm, K., Mikhaylov bi, Ba, L., Milano ag, J., Milosevic t, A., Mischke az, A. N., Mishra aq, D., Mis ́kowiec cl, C., Mitu be, J., Mlynarz dt, B., Mohanty dq, Bu, L., Molnar aw, Du, L., Montaño Zetina j, M., Monteno cz, E., Montes i, M., Morando aa, D. A., Moreira De Godoy dg, S., Moretto aa, A., Morreale dj, A., Morsch ag, V., Muccifora bn, E., Mudnic dc, S., Muhuri dq, M., Mukherjee dq, H., Müller ag, M. G., Munhoz dg, S., Murray bh, L., Musa ag, B. K., Nandi ap, R., Nania ct, E., Nappi c, C., Nattrass dk, T. K., Nayak dq, S., Nazarenko cn, A., Nedosekin ba, M., Nicassio cl, Ad, M., Niculescu ag, B. S., Nielsen bv, S., Nikolaev co, S., Nikulin co, V., Nikulin ca, B. S., Nilsen cb, M. S., Nilsson t, F., Noferini k, P., Nomokonov bi, G., Nooren az, A., Nyanin co, A., Nyatha ap, J., Nystrand q, H., Oeschler ch, Au, S. K., Oh am, S., Oh dv, L., Olah du, J., Oleniacz d, A. C., Oliveira Da Silva dg, J., Onderwaater cl, C., Oppedisano cz, A., Ortiz Velasquez ae, A., Oskarsson ae, J., Otwinowski cl, K., Oyama ch, Y., Pachmayer ch, M., Pachr aj, P., Pagano ab, G., Paic ́ bf, F., Painke al, C., Pajares o, S. K., Pal dq, A., Palaha cq, A., Palmeri cv, V., Papikyan a, G. S., Pappalardo cv, W. J., Park cl, A., Passfeld av, D. I., Patalakha ax, V., Paticchio c, B., Paul cp, T., Pawlak d, T., Peitzmann az, H., Pereira Da Costa m, E., Pereira De Oliveira Filho dg, D., Peresunko co, C. E., Pérez Lara bw, D., Perrino ad, W., Peryt d, A., Pesci ct, Y., Pestov d, V., Petrácˇek aj, M., Petran aj, M., Petris bt, P., Petrov cq, M., Petrovici bt, C., Petta z, Piano, Stefano, M., Pikna ai, P., Pillot da, O., Pinazza ag, L., Pinsky di, N., Pitz at, D. B., Piyarathna di, M., Planinic dn, Cm, M., Płoskon ́ bp, J., Pluta d, S., Pochybova du, P. L. M., Podesta Lerma df, M. G., Poghosyan ag, B., Polichtchouk ax, A., Pop bt, S., Porteboeuf Houssais bl, V., Pospíšil aj, B., Potukuchi cf, S. K., Prasad dt, R., Preghenella k, F., Prino cz, C. A., Pruneau dt, I., Pshenichnov ay, G., Puddu u, V., Punin cn, J., Putschke dt, H., Qvigstad t, A., Rachevski cy, A., Rademakers ag, J., Rak dj, A., Rakotozafindrabe m, L., Ramello ac, S., Raniwala cg, R., Raniwala cg, S. S., Räsänen an, B. T., Rascanu at, D., Rathee cc, W., Rauch ag, A. W., Rauf n, V., Razazi u, K. F., Read dk, J. S., Real bm, K., Redlich b, R. J., Reed dv, A., Rehman q, P., Reichelt at, M., Reicher az, F., Reidt ag, R., Renfordt at, A. R., Reolon bn, A., Reshetin ay, F., Rettig al, J. P., Revol ag, K., Reygers ch, L., Riccati cz, R. A., Ricci bo, T., Richert ae, M., Richter t, P., Riedler ag, W., Riegler ag, F., Riggi z, A., Rivetti cz, M., Rodríguez Cahuantzi b, A., Rodriguez Manso bw, K., Røed q, T, E., Rogochaya bi, S., Rohni cf, D., Rohr al, D., Röhrich q, R., Romita bx, Cl, F., Ronchetti bn, P., Rosnet bl, S., Rossegger ag, A., Rossi ag, P., Roy cp, C., Roy aw, A. J., Rubio Montero i, Rui, Rinaldo, R., Russo w, E., Ryabinkin co, A., Rybicki dd, S., Sadovsky ax, K., Šafarˇík ag, R., Sahoo aq, P. K., Sahu bd, J., Saini dq, H., Sakaguchi ao, S., Sakai bp, Bn, D., Sakata dm, C. A., Salgado o, J., Salzwedel r, S., Sambyal cf, V., Samsonov ca, X., Sanchez Castro bf, Aw, L., Šándor bb, A., Sandoval bg, M., Sano dm, G., Santagati z, R., Santoro k, D., Sarkar dq, E., Scapparone ct, F., Scarlassara aa, R. P., Scharenberg cj, C., Schiaua bt, R., Schicker ch, C., Schmidt cl, H. R., Schmidt af, S., Schuchmann at, J., Schukraft ag, M., Schulc aj, T., Schuster dv, Y., Schutz ag, K., Schwarz cl, K., Schweda cl, G., Scioli y, E., Scomparin cz, R., Scott dk, P. A., Scott cq, G., Segato aa, I., Selyuzhenkov cl, J., Seo ck, S., Serci u, E., Serradilla i, Bg, A., Sevcenco be, A., Shabetai da, G., Shabratova bi, R., Shahoyan ag, S., Sharma cf, N., Sharma dk, K., Shigaki ao, K., Shtejer h, Y., Sibiriak co, S., Siddhanta cu, T., Siemiarczuk b, D., Silvermyr bz, C., Silvestre bm, G., Simatovic dn, R., Singaraju dq, R., Singh cf, S., Singha dq, V., Singhal dq, B. C., Sinha dq, T., Sinha cp, B., Sitar ai, M., Sitta ac, T. B., Skaali t, K., Skjerdal q, R., Smakal aj, N., Smirnov dv, R. J. M., Snellings az, R., Soltz bq, M., Song dw, J., Song ck, C., Soos ag, F., Soramel aa, M., Spacek aj, I., Sputowska dd, M., Spyropoulou Stassinaki cd, B. K., Srivastava cj, J., Stachel ch, I., Stan be, G., Stefanek b, M., Steinpreis r, E., Stenlund ae, G., Steyn bh, J. H., Stiller ch, D., Stocco da, M., Stolpovskiy ax, P., Strmen ai, A. A. P., Suaide dg, M. A., Subieta Vásquez w, T., Sugitate ao, C., Suire ar, M., Suleymanov n, R., Sultanov ba, M., Šumbera by, T., Susa cm, T. J. M., Symons bp, A., Szanto de Toledo dg, I., Szarka ai, A., Szczepankiewicz ag, M., Szyman ́ ski d, J., Takahashi dh, M. A., Tangaro ad, J. D., Tapia Takaki ar, A., Tarantola Peloni at, A., Tarazona Martinez ag, A., Tauro ag, G., Tejeda Muñoz b, A., Telesca ag, C., Terrevoli ad, A., Ter Minasyan co, Br, J., Thäder cl, D., Thomas az, R., Tieulent do, A. R., Timmins di, A., Toia cw, H., Torii dl, V., Trubnikov c, W. H., Trzaska dj, T., Tsuji dl, A., Tumkin cn, R., Turrisi cw, T. S., Tveter t, J., Ulery at, K., Ullaland q, J., Ulrich a, A., Uras do, G. M., Urciuoli cx, G. L., Usai u, M., Vajzer by, M., Vala bb, Bi, L., Valencia Palomo ar, P., Vande Vyvre ag, L., Vannucci bo, J. W., Van Hoorne ag, M., van Leeuwen az, A., Vargas b, R., Varma ap, M., Vasileiou cd, A., Vasiliev co, V., Vechernin dp, M., Veldhoen az, M., Venaruzzo v, E., Vercellin w, S., Vergara b, R., Vernet g, M., Verweij dt, Az, L., Vickovic dc, G., Viesti aa, J., Viinikainen dj, Z., Vilakazi bh, O., Villalobos Baillie cq, A., Vinogradov co, L., Vinogradov dp, Y., Vinogradov cn, T., Virgili ab, Y. P., Viyogi dq, A., Vodopyanov bi, M. A., Völkl ch, S., Voloshin dt, K., Voloshin ba, G., Volpe ag, B., von Haller ag, I., Vorobyev dp, D., Vranic ag, J., Vrláková ak, B., Vulpescu bl, A., Vyushin cn, B., Wagner q, V., Wagner aj, J., Wagner cl, Y., Wang ch, Y., Wang f, M., Wang f, D., Watanabe dm, K., Watanabe dm, M., Weber di, J. P., Wessels av, U., Westerhoff av, J., Wiechula af, J., Wikne t, M., Wilde av, G., Wilk b, J., Wilkinson ch, M. C. S., Williams ct, B., Windelband ch, M., Winn ch, C., Xiang f, C. G., Yaldo dt, Y., Yamaguchi dl, H., Yang m, P., Yang f, S., Yang q, S., Yano ao, S., Yasnopolskiy co, J., Yi ck, Z., Yin f, I. K., Yoo ck, I., Yushmanov co, Zaccolo bv, V., C., Zach aj, C., Zampolli ct, S., Zaporozhets bi, A., Zarochentsev dp, P., Závada bc, N., Zaviyalov cn, H., Zbroszczyk d, P., Zelnicek a, I. S., Zgura be, M., Zhalov ca, F., Zhangf, Y., Zhangf, H., Zhangf, X., Zhangbp, Bl, F, D., Zhouf, Y., Zhouaz, F., Zhouf, X., Zhuf, J., Zhuf, H., Zhu f, A., Zichichi k, M. B., Zimmermann av, A., Zimmermann ch, G., Zinovjev c, Y., Zoccarato do, M., Zynovyev c, M., Zyzak, and Contin, Giacomo

Subjects
hadron production, p-Pb collisions, Multiplicity, Multiplicity dependence, p-Pb collision, 5.02 TeV, Nuclear Experiment
Abstract

Inthis Letter, comprehensive results on π±,K±,K0S, p(pbar) and Λ(Λbar) production at mid-rapidity (0< yCMS < 0.5) in p–Pb collisions at √sNN = 5.02 TeV, measured by the ALICE detector at the LHC, are reported. The transverse momentum distributions exhibit a hardening as a function of event multiplicity, which is stronger for heavier particles. This behavior is similar to what has been observed in pp and Pb–Pb collisions at the LHC. The measured pT distributions are compared to d–Au, Au–Au and Pb–Pb results at lower energy and with predictions based on QCD-inspired and hydrodynamic models.

Published
2014

13. Polimorfismos do gene bola-drb3 em rebanhos bovinos leiteiros 5/8 girolando e holandês no estado de pernambuco

Author

Vilaça, L.F., Diniz, W.J.S., Melo, T.F., Oliveira, J.C.V., Guido, S.I., Brito, C.E.V.L., Costa, N.A., Santoro, K. R., Vilaça, L.F., Diniz, W.J.S., Melo, T.F., Oliveira, J.C.V., Guido, S.I., Brito, C.E.V.L., Costa, N.A., and Santoro, K. R.

Abstract

The BoLA region (Bovine Lymphocyte Antigen), has been paid attention to because of its alleles having influence on immune functions and production traits. The present study aimed at the identification and association of BoLA-DRB3.2 gene polymorphisms in 145 5/8 Girolando and Holstein dairy cows, in reference herds in the state of Pernambuco. 39 alleles with frequencies ranging from 0.42 to 15.97 % were identified, and the most common alleles were 0101 (6.13 %), R (14.11 %) and 1101 (14.72 %).There were low similarity values, demonstrating a greater genetic variability among animals. The distance between the 5/8 Girolando and Holstein, was 0.075. Observed heterozygosity values (Ho) were lower than those for expected heterozygosity (He). There was a high BoLA-DRB3.2 gene polymorphism for the herds and a high number of alleles that had positive effects on milk production, especially for 16 and 0101 alleles., A região BoLA (Bovine Lymphocyte Antigen) tem recebido atenção por seus alelos terem ação sobre funções imunológicas e características de produção. O presente estudo teve por objetivo a identificação e associação dos polimorfismos do gene BoLA-DRB3.2 em 145 vacas leiteiras 5/8 Girolando e Holandês, em rebanhos de referência no Estado de Pernambuco. Identificaram-se 39 alelos com frequências alélicas variando entre 0,42 e 15,97 %, sendo os alelos mais frequentes 0101 (6,13 %), R (14,11 %) e 1101 (14,72 %). Verificaram-se valores baixos de similaridade, demonstrando maior variabilidade genética entre os animais. A estimativa de distância entre os rebanhos Holandês e 5/8 Girolando, foi de 0,075. A heterozigosidade observada (Ho) apresentou valores menores que a heterozigosidade esperada (He). Observou-se um elevado polimorfismo do gene BoLA-DRB3.2 para os rebanhos estudados e um elevado número de alelos que desempenharam efeitos positivos na produção de leite, com destaque para os alelos 16 e 0101.

Published
2016

27. An interdisciplinary team approach to the management of pediatric feeding and swallowing disorders.

Author

Miller CK, Burklow KA, Santoro K, Kirby E, Mason D, and Rudolph CD

Abstract

Children with complex feeding problems frequently are involved with many health care services given the multiple medical and developmental issues impacting on feeding progress. The key to providing well-coordinated clinical services for these patients is to use an interdisciplinary team approach. In this article we describe a model of interdisciplinary team care for medically complex children with chronic feeding, swallowing, nutrition, and growth problems. A description of the functional roles of each of the disciplines represented on the team (nursing, nutrition, speech pathology, occupational therapy, psychology, and gastroenterology) is provided. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

29. Presence of Somatic Cells in Murrah Buffaloes in Northeast of Brazil.

Author

Barbosa, S. B. Paes, Batista, Â. M. Vieira, Jatobá, R. Bezerra, Silva, M. J. Araújo, and Santoro, K. R.

Subjects
MASTITIS, WATER buffalo, SOMATIC cells, MILK yield, LACTOSE, DAIRY industry, PREVENTIVE medicine, CYTOMETRY, DISEASES
Abstract

Mastitis is a chronic disease and can affect the various species of cattle, including buffaloes, causing great damage to the milk production chain. In a way to control mastitis, the somatic cell count (SCC) has been used as a tool for management of the dairy herd. This study evaluated the presence of somatic cells in Murrah buffaloes in northeastern Brazil, between May/2008 and October/2009. We used information from 3186 SCC. In absence of linearity with the production of milk, the SCC was transformed into somatic cell score (SCS), with [log2 (SCC/100) + 3]. The data were analyzed by SAS (2008) and the correlations of SCC and SCS with the composition of milk were considered. The means and standard deviations of SCC and SCS×103 were 584.6 ± 1266.4 ×103 and 2.57 ± 1.07, respectively. More than half of production (56.88%) had values of SCC below 200×103. The correlations of SCC and SCS with the characteristics of the composition of milk were all significant, with the exception of SCC and solids. Lactose showed negative associations with SCC (- 0.44) and SCS (- 0.49), which is extremely undesirable, since this component is of great importance for the dairy industry. The results of SCC suggest the need to implement a control program to reduce sub-clinical mastitis in the herd. [ABSTRACT FROM AUTHOR]

Published
2010

36. Epidemiology and spatial distribution of Echinococcus granulosus in sheep and goats slaughtered in a hyperendemic European Mediterranean area

Author

Paola Pepe, Giuseppe Cringoli, Kleber Régis Santoro, Paola Cociancic, Rafael Antonio Nascimento Ramos, Maria Elena Morgoglione, Maria Paola Maurelli, Laura Rinaldi, Edyniesky Ferrer-Miranda, Leucio Camara Alves, Antonio Bosco, Alessandra Amadesi, Bosco, A., Alves, L. C., Cociancic, P., Amadesi, A., Pepe, P., Morgoglione, M. E., Maurelli, M. P., Ferrer-Miranda, E., Santoro, K. R., Nascimento Ramos, R. A., Rinaldi, L., and Cringoli, G.

Subjects
Veterinary medicine, Endemic Diseases, Sheep Disease, Infectious and parasitic diseases, RC109-216, Zoonoses, Epidemiology, Prevalence, Zoonose, Echinococcus granulosus, Cystic echinococcosi, biology, Cysts, Goats, Zoonosis, Echinococcosis, Echinococcus granulosu, Infectious Diseases, Italy, Goat, Mediterranean area, Echinococcosi, Livestock, Abattoirs, medicine.medical_specialty, Genotype, Sheep Diseases, Endemic Disease, Spatial distribution, Goat Disease, parasitic diseases, medicine, Animals, Spatial Analysis, Goat Diseases, Sheep, Animal, business.industry, Research, Spatial Analysi, medicine.disease, biology.organism_classification, Cystic echinococcosis, Cyst, Parasitology, business
Abstract

Background Cystic echinococcosis (CE) is a worldwide parasitic zoonosis caused by the larval stage of Echinococcus granulosus sensu lato affecting livestock, particularly sheep and goats. However, often this parasitosis is underestimated. For this reason, this study aimed to evaluate the epidemiological features and spatial distribution of CE in sheep and goats slaughtered in a hyperendemic Mediterranean area. Methods A survey was conducted in the Basilicata region (southern Italy) from 2014 to 2019. A total of 1454 animals (1265 sheep and 189 goats) from 824 farms were examined for hydatid cyst detection by visual inspection, palpation and incision of target organs. All the CE cysts were counted and classified into five morphostructural types (unilocular, multiseptate, calcified, caseous and hyperlaminated). Molecular analysis was performed on 353 cysts. For spatial analysis, a kriging interpolation method was used to create risk maps, while clustering was assessed by Moran’s I test. Results CE prevalence of 72.2% (595/824) and 58.4% (849/1454) was observed at the farm and animal levels, respectively, with higher values in sheep (62.9%) than goats (28.0%). The liver and lungs were the most frequently infected organs in both sheep and goats. Most of recovered cysts were of the calcified and multiseptate morphotypes. All the isolates were identified as E. granulosus sensu stricto (genotypes G1–G3). Spatial distribution showed a moderate clustering of positive animals. Conclusion The findings of this study can be used to better understand the eco-epidemiology of echinococcosis and to improve CE surveillance and prevention programs in regions highly endemic for CE. Graphical abstract

Published
2021

37. Italian report on RARE epilepsies (i-RARE): A consensus on multidisciplinarity.

Author

Riva A, Coppola A, Bisulli F, Verrotti A, Bagnasco I, Elia M, Darra F, Lattanzi S, Meletti S, La Neve A, Di Gennaro G, Brambilla I, Santoro K, Prisco T, Macari F, Gambardella A, di Bonaventura C, Balestrini S, Marini C, Pruna D, Capovilla G, Specchio N, Gobbi G, and Striano P

Subjects
Humans, Italy, Epilepsy therapy, Consensus, Delphi Technique, Rare Diseases therapy
Abstract

Objective: Rare and complex epilepsies encompass a diverse range of disorders characterized by seizures. We aimed to establish a consensus on key issues related to these conditions through collaboration among experienced neurologists, neuropediatricians, and patient advocacy representatives., Methods: Employing a modified Delphi method, a scientific board comprising 20 physicians and 4 patient advocacy representatives synthesized existing literature with their expertise to formulate statements on contentious topics. A final 32-member expert panel, representing diverse regions of Italy, validated these statements through a two-round voting process, with consensus defined as an average score ≥7., Results: Sixteen statements reached a consensus, emphasizing the necessity for epidemiological studies to ascertain the true prevalence of rare epilepsies. Etiology emerged as a crucial factor influencing therapeutic strategies and outcome prediction, with particular concern regarding prolonged and tonic-clonic seizures. The importance of early implementation of specific drugs and non-pharmacological interventions in the treatment algorithm for developmental and epileptic encephalopathies (DEEs) was underscored. Multidisciplinary care involving experts with diverse skills was deemed essential, emphasizing non-seizure outcomes in adolescence and adulthood., Significance: This national consensus underscores the imperative for personalized, comprehensive, and multidisciplinary management of rare epilepsies/DEEs. It advocates for increased research, particularly in epidemiology and therapeutic approaches, to inform clinical decision-making and healthcare policies, ultimately enhancing patients' outcomes., Plain Language Summary: The modified Delphi method is broadly used to evaluate debated topics. In this work, we sought the consensus on integrated and social care in epilepsy management. Both representatives of high-level epilepsy centers and patients' caregivers were directly involved., (© 2024 The Author(s). Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)

Published
2024
Full Text
View/download PDF

38. What are the perceived unmet needs for patient care, education, and research among genitourinary cancer nurses in Australia? A mixed method study.

Author

Paterson C, Anderson H, Rosano M, Cowan D, Schulz D, Santoro K, Forshaw T, Hawks C, and Roberts N

Abstract

Objective: Specialist genitourinary (GU) nurses provide care to a broad and diverse group of patients diagnosed with kidney, bladder, prostate, testicular, adrenal, and penile cancer. The purpose of this study was to identify GU cancer nurse perspectives of perceived unmet needs in service provision, specific educational and research priorities., Methods: A concurrent mixed methods study design incorporated quantitative and qualitative data collection from the GU Cancer nurses workforce in Australia. Quantitative data collected using an electronic survey instrument and were analysed using descriptive statistics. Qualitative data collected through semi-structured interviews and coded for thematic analysis. Ethical approval was gained., Results: Fifty responses were received from the electronic survey. 39/50 (78%) were female and 35 (70%) were metropolitan based. The highest domains of perceived unmet needs related to psychological/emotional needs - 17/23 (74%), intimacy needs - 15/23 (65%) and informational needs - 13/23 (57%). The themes from the qualitative interviews identified: (1) Patient needs - lack of tumour specific contact for cancer patients, fragmented delivery of cancer care, perception of better access to supportive care for public patients, lack of access to supportive care screening tools for needs assessment. (2) Educational needs - lack of GU specific cancer educational resources/learning opportunities and barriers to accessing educational opportunities. (3) Research priorities - impact on carers/partners, specific needs of different GU cancers, future focus on genetic testing/counselling, interventions for financial toxicity and development of models of care for geriatric GU patients., Conclusions: Specialist GU cancer nurses support a broad group of patients. Given the prominence of addressing unmet cancer care needs among people with GU cancers in this study, cancer nursing as a discipline alongside the multidisciplinary team, requires innovative solutions to overcome fragmented care which is often highly complex, and develop individualised and integrated care across the cancer care continuum. We encourage clinicians, researchers, policy makers, people affected by cancer, and their care networks, to continue to drive innovation by (1) Embedding an integrated approach to cancer nursing, (2) Implementation of shared care, (3) Implementation of patient navigation, (4) Embracing emerging technologies, (5) Future focus on education, and (6) Future focus on nurse-led research., (© 2024 The Author(s).)

Published
2024
Full Text
View/download PDF

39. Clinical and functional outcomes for risk-appropriate treatments for prostate cancer.

Author

Tiruye T, O'Callaghan M, Ettridge K, Moretti K, Jay A, Higgs B, Santoro K, Kichenadasse G, and Beckmann K

Abstract

Objectives: To describe real-world clinical and functional outcomes in an Australian cohort of men with localised prostate cancer according to treatment type and risk category., Subjects and Methods: Men diagnosed from 2008 to 2018 who were enrolled in South Australian Prostate Cancer Clinical Outcomes Collaborative registry-a multi-institutional prospective clinical registry-were studied. The main outcome measures were overall survival, cancer-specific survival, decline in functional outcomes, biochemical recurrence and transition to active treatment following active surveillance. Multivariable adjusted models were applied to estimate outcomes., Results: Of the 8513 eligible men, majority of men (46%) underwent radical prostatectomy (RP) followed by external beam radiation therapy with or without androgen deprivation therapy (EBRT +/- ADT) in 22% of the cohort. Five-year overall survival was above 91%, and 5-year prostate cancer-specific survival was above 97% in the low- and intermediate-risk categories across all treatments. Five-year prostate cancer-specific survival in the active surveillance group was 100%. About 37% of men with high-risk disease treated with RP and 17% of men treated with EBRT +/- ADT experienced biochemical recurrence within 5 years of treatment. Of men on active surveillance, 15% of those with low risk and 20% with intermediate risk converted to active treatment within 2 years. The decline in urinary continence and sexual function 12 months after treatment was greatest among men who underwent RP while the decline in bowel function was greatest for men who received EBRT +/- ADT., Conclusion: This contemporary real-world evidence on risk-appropriate treatment outcomes helps inform treatment decision-making for clinicians and patients., Competing Interests: No conflicts of interest., (© 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company.)

Published
2023
Full Text
View/download PDF

40. Planning and Implementing an Organizational Health Assessment in a Community Mental Health Setting.

Author

Lee S, Pasquarella FJ, De La Peza D, Lizano EL, and Santoro K

Subjects
Humans, Workforce, Personnel Turnover, Health Workforce, Mental Health, Mental Health Services
Abstract

The workforce is the essential driver behind mental health service provision and the most valuable asset to any community mental health organization. To build and retain a stable and healthy workforce, systematic recruitment and retention strategies are needed. An organizational health assessment is a valuable tool in developing targeted organizational interventions to create a positive work environment and retain an engaged workforce. Starting in 2017, a large community mental health organization in Southern California implemented such an assessment to drive actionable steps to improve employee experience and decrease turnover. This case study describes the development and implementation of a low-cost organizational health assessment through five phases: development of the assessment, data collection, analysis, metrics and data visualization, and dissemination of findings and development of interventions. Key lessons learned include the importance of utilizing the findings and achieving staff and leadership buy-in., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2023
Full Text
View/download PDF

41. Factors impacting on sexual function among men on active surveillance for prostate cancer.

Author

Tiruye T, O'Callaghan M, Ettridge K, Jay A, Santoro K, Moretti K, and Beckmann K

Subjects
Male, Humans, Quality of Life, Prospective Studies, Watchful Waiting, Australia, Prostatectomy adverse effects, Erectile Dysfunction epidemiology, Erectile Dysfunction etiology, Prostatic Neoplasms pathology
Abstract

Background: Active surveillance (AS) aims to reduce overtreatment and minimize the negative side effects of radical therapies (i.e., prostatectomy or radiotherapy) while preserving quality of life. However, a substantial proportion of men can experience a decline in sexual function during AS follow-up. The aim of this study was to identify predictors of declining sexual function among men on AS., Methods: Men enrolled from 2008 to 2018 in the South Australian Prostate Cancer Clinical Outcomes Collaborative registry-a prospective clinical registry-were studied. Sexual function outcomes were measured using expanded prostate cancer index composite (EPIC-26) at baseline and 12-months postdiagnosis. Multivariable regression models adjusted for baseline score and other sociodemographic and clinical factors were applied to identify predictors of sexual function score at 12-months., Results: A total of 554 men were included. Variables that showed significant association with decline in sexual function score at 12-months were: having two or more biopsies after diagnosis (mean change score (MCS): -16.3, p < 0.001) compared with no biopsy, higher number of positive biopsy cores (MCS: -1.6, p = 0.004), being in older age category (above 70 vs. below 60: MCS: -16.7, p < 0.001; 65-70 vs. below 60: MCS: -9.7, p = 0.024), having had depression (MCS: -9.0, p = 0.020), and impaired physical function (MCS: -10.0, p = 0.031). Greater socioeconomic advantage (highest vs. lowest quintile: MCS: 15.7, p = 0.022) and year of diagnosis (MCS: 2.6 for every year, p < 0.001) were positively associated with 12-months sexual function score. Neither biopsy type, biopsy timing nor PSA velocity were associated with declines in sexual function., Conclusions: Our findings suggest that multiple factors affected sexual function during AS. Interventions toward reducing the number of biopsies through less invasive monitory approaches, screening for physical and mental well-being, and targeted emotional support and counseling services may be helpful for men on AS., (© 2023 The Authors. The Prostate published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

42. Patient-reported functional outcome measures and treatment choice for prostate cancer.

Author

Tiruye T, O'Callaghan M, Moretti K, Jay A, Higgs B, Santoro K, Boyle T, Ettridge K, and Beckmann K

Subjects
Male, Humans, Prospective Studies, Australia, Prostatectomy, Patient Reported Outcome Measures, Treatment Outcome, Quality of Life, Prostatic Neoplasms radiotherapy, Prostatic Neoplasms surgery, Brachytherapy
Abstract

Background: The aim of this study was to describe changes in patient-reported functional outcome measures (PROMs) comparing pre-treatment and 12 months after radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy and active surveillance (AS)., Methods: Men enrolled from 2010 to 2019 in the South Australian Prostate Cancer Clinical Outcomes Collaborative registry a prospective clinical registry were studied. Urinary, bowel, and sexual functions were measured using Expanded Prostate Cancer Index Composite (EPIC-26) at baseline and 12 months post-treatment. Higher scores on the EPIC-26 indicate better function. Multivariable regression models were applied to compare differences in function and extent of bother by treatment., Results: Of the 4926 eligible men, 57.0% underwent RP, 20.5% EBRT, 7.0% brachytherapy and 15.5% AS. While baseline urinary and bowel function varied little across treatment groups, sexual function differed greatly (adjusted mean scores: RP = 56.3, EBRT = 45.8, brachytherapy = 61.4, AS = 52.8; p < 0.001). Post-treatment urinary continence and sexual function declined in all treatment groups, with the greatest decline for sexual function after RP (adjusted mean score change - 28.9). After adjustment for baseline differences, post-treatment sexual function scores after EBRT (6.4; 95%CI, 0.9-12.0) and brachytherapy (17.4; 95%CI, 9.4-25.5) were higher than after RP. Likewise, urinary continence after EBRT (13.6; 95%CI, 9.0-18.2), brachytherapy (10.6; 95%CI, 3.9-17.3) and AS (10.6; 95%CI, 5.9-15.3) were higher than after RP. Conversely, EBRT was associated with lower bowel function (- 7.9; 95%CI, - 12.4 to - 3.5) than RP. EBRT and AS were associated with lower odds of sexual bother (OR 0.51; 95%CI, 0.29-0.89 and OR 0.60; 95%CI, 0.38-0.96, respectively), and EBRT with higher odds of bowel bother (OR 2.01; 95%CI, 1.23-3.29) compared with RP., Conclusion: The four common treatment approaches for prostate cancer were associated with different patterns of patient-reported functional outcomes, both pre- and 12 months post-treatment. However, after adjustment, RP was associated with a greater decline in urinary continence and sexual function than other treatments. This study underscores the importance of collecting baseline PROMs to interpret post-treatment functional outcomes., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

43. An Italian consensus on the management of Lennox-Gastaut syndrome.

Author

Riva A, Coppola A, Bonaventura CD, Elia M, Ferlazzo E, Gobbi G, Marini C, Meletti S, Romeo A, Santoro K, Verrotti A, Capovilla G, and Striano P

Subjects
Anticonvulsants therapeutic use, Clobazam therapeutic use, Consensus, Fenfluramine therapeutic use, Humans, Lamotrigine, Quality of Life, Topiramate therapeutic use, Valproic Acid therapeutic use, Cannabidiol therapeutic use, Lennox Gastaut Syndrome diagnosis, Lennox Gastaut Syndrome drug therapy
Abstract

Purpose: Although international guidelines exist, the clinical heterogeneity of Lennox-Gastaut syndrome (LGS) and the increasing availability of new and repurposed drugs (e.g., fenfluramine and cannabidiol) requires a practical guide to patient management in the clinical context. We report the results of a consensus survey among 42 Italian experts in the diagnosis and treatment of LGS., Methods: The consensus procedure followed a modified Delphi approach. Statements were formulated, based on the most recent published evidence and the clinicians' personal experience, then discussed, and agreed upon by the experts through a two-round voting procedure. Approval of a statement was reached with an average score ≥7., Results: Thirteen statements dealing with three main topics (i.e., clinical diagnosis and prognosis, impact on the Quality of Life (QoL), and treatment strategies) were generated. Six statements achieved a level of agreement sufficient for approval on the first voting round. Following the discussion and a few consequent amendments, most of the statements increased their level of agreement and all 13 were approved., Conclusions: Overall, the statements draw a slightly more benign picture of this rare and severe disease, highlighting the possibility of remission - albeit modest -, an apparent trend towards lower mortality, and the availability of several effective drugs, to which greater accessibility would be hoped for. Valproate remains a major therapeutic option in LGS patients although lamotrigine, rufinamide, topiramate, cannabidiol, and clobazam are popular therapeutic options in Italy, allowing for a tailor-made antiseizure therapy., Competing Interests: Declaration of Competing Interest A.R has received honoraria from Kolfarma s.r.l, Proveca Pharma Ltd, and PTC Therapeutics. P. S has served on a scientific advisory board for the Italian Agency of the Drug (AIFA); has received honoraria from GW pharma, Kolfarma s.r.l., Proveca Pharma Ltd, and Eisai Inc.; and has received research support from the Italian Ministry of Health and Fondazione San Paolo. All the other authors do not report conflict of interest., (Copyright © 2022 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

44. Lipids and Long Chain Polyunsaturated Fatty Acids in Preterm Infants.

Author

Santoro K and Martin CR

Subjects
Enteral Nutrition, Fatty Acids, Unsaturated therapeutic use, Humans, Infant, Infant Nutritional Physiological Phenomena, Infant, Newborn, Fatty Acids, Infant, Premature
Abstract

Fatty acids are critical bioactives for fetal and neonatal development. Premature delivery and current nutritional strategies pose several challenges in restoring fatty acid balance in the preterm infant. The impact on fatty acid balance and outcomes using lipid emulsions, enteral nutrition, and enteral supplements are reviewed, including a summary of the most recent large clinical trials of enteral fatty acid supplementation for the preterm infant. Research gaps remain in successfully implementing nutritional strategies to optimize fatty acid status in preterm infants., Competing Interests: Disclosure KLS received funding support from the grant T32 HD 098061 for completion of this review.., (Copyright © 2022 Elsevier Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

45. First Multi-Target Application of Exclusion Net in Nectarine Orchards: Effectiveness against Pests and Impact on Beneficial Arthropods, Postharvest Rots and Fruit Quality.

Author

Candian V, Pansa MG, Santoro K, Spadaro D, Briano R, Peano C, Tavella L, and Tedeschi R

Abstract

Over the past few years, there has been an increasing interest in the development of alternative pest control strategies to reduce environmental impact. In this contest, exclusion nets have been evaluated as a sustainable alternative to pesticides. In this study, the use of a photoselective exclusion net was investigated in semi-field conditions as a potential strategy to protect nectarine orchards from different pests (i.e., fruit moths, Halyomorpha halys and Drosophila suzukii ) in NW Italy. The presence and abundance of pest populations inside and outside the net, as well as the damage they caused on fruits, were evaluated. Moreover, any possible effects of the net on beneficial arthropods, postharvest rots and fruit quality and nutraceutical parameters were considered. The exclusion net significantly reduced pest populations. At harvest, fruit damage caused by Grapholita molesta and H. halys in netted plots was reduced up to 90% and to 78%, respectively, compared with insecticide-treated plots. The exclusion net allowed the production of healthier fruits with a strong reduction of insecticide treatments (up to seven less) and of their related costs without any negative impact on postharvest rots, neither fruit quality nor nutraceutical properties.

Published
2021
Full Text
View/download PDF

46. Photoselective exclusion netting in apple orchards: effectiveness against pests and impact on beneficial arthropods, fungal diseases and fruit quality.

Author

Candian V, Pansa MG, Santoro K, Spadaro D, Tavella L, and Tedeschi R

Subjects
Animals, Fruit, Insect Control, Plant Diseases, Arthropods, Malus microbiology
Abstract

Background: Frequent pesticide treatments in fruit orchards increase hazards for workers, consumers and the environment. Moreover, the indiscriminate and excessive use of pesticides often induces resistance in pests. In the past few years, physical exclusion strategies have been proposed as an alternative for the control of insect pests. The goal of this study was to evaluate the effectiveness of anti-hail photoselective netting in protecting apples against key and emerging pests, as well as the impact on beneficial arthropods, fungal diseases and fruit quality., Results: In netted plots, a significant reduction in pest populations, i.e. fruit moths, Halyomorpha halys (Stål) and Drosophila suzukii (Matsumura), was recorded in comparison with un-netted controls. Moreover, the damage on fruits caused by H. halys was reduced up to 62% compared with insecticidal treatments. The net did not negatively affect the abundance of predators and the incidence of post-harvest rot. In addition, the incidence of bitter pit on apple was reduced up to 52%. Furthermore, fruit quality was unaffected by the net coverage (both at harvest and after 4 months of storage)., Conclusion: Anti-hail photoselective pearl netting proved a promising exclusion system that can prevent attack by more than one insect pest at a time, allowing for a strong reduction in insecticide treatments and relative costs. At the same time, the netting did not negatively influence the presence of predators, the incidence of fungal disease or fruit quality. © 2019 Society of Chemical Industry., (© 2019 Society of Chemical Industry.)

Published
2020
Full Text
View/download PDF

47. Thyme and Savory Essential Oil Efficacy and Induction of Resistance against Botrytis cinerea through Priming of Defense Responses in Apple.

Author

Banani H, Olivieri L, Santoro K, Garibaldi A, Gullino ML, and Spadaro D

Abstract

The efficacy of thyme and savory essential oils were investigated against Botrytis cinerea on apple fruit. Apples treated with thyme and savory essential oils showed significantly lower gray mold severity and incidence. Thyme essential oil at 1% concentration showed the highest efficacy, with lower disease incidence and smaller lesion diameter. The expression of specific pathogenesis-related (PR) genes PR-8 and PR-5 was characterized in apple tissues in response to thyme oil application and B. cinerea inoculation. After 6 h of pathogen inoculation, thyme essential oil induced a 2.5-fold increase of PR-8 gene expression compared to inoculated fruits. After 24 h of inoculation, PR-8 was highly induced (7-fold) in both thyme oil-treated and untreated apples inoculated with B. cinerea . After 48 h of inoculation, PR-8 expression in thyme-treated and inoculated apples was 4- and 6-fold higher than in inoculated and water-treated apples. Neither thyme oil application nor B. cinerea inoculation markedly affected PR-5 expression. These results suggest that thyme oil induces resistance against B. cinerea through the priming of defense responses in apple fruit, and the PR-8 gene of apple may play a key role in the mechanism by which thyme essential oil effectively inhibits gray mold in apple fruit., Competing Interests: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Published
2018
Full Text
View/download PDF

48. Thyme and Savory Essential Oil Vapor Treatments Control Brown Rot and Improve the Storage Quality of Peaches and Nectarines, but Could Favor Gray Mold.

Author

Santoro K, Maghenzani M, Chiabrando V, Bosio P, Gullino ML, Spadaro D, and Giacalone G

Abstract

The effect of biofumigation, through slow-release diffusors, of thyme and savory essential oils (EO), was evaluated on the control of postharvest diseases and quality of peaches and nectarines. EO fumigation was effective in controlling postharvest rots. Naturally contaminated peaches and nectarines were exposed to EO vapors for 28 days at 0 °C in sealed storage cabinets and then exposed at 20 °C for five days during shelf-life in normal atmosphere, simulating retail conditions. Under low disease pressure, most treatments significantly reduced fruit rot incidence during shelf-life, while, under high disease pressure, only vapors of thyme essential oil at the highest concentration tested (10% v / v in the diffusor) significantly reduced the rots. The application of thyme or savory EO favored a reduction of brown rot incidence, caused by Monilinia fructicola , but increased gray mold, caused by Botrytis cinerea . In vitro tests confirmed that M. fructicola was more sensitive to EO vapors than B. cinerea . Essential oil volatile components were characterized in storage cabinets during postharvest. The antifungal components of the essential oils increased during storage, but they were a low fraction of the volatile organic compounds in storage chambers. EO vapors did not influence the overall quality of the fruit, but showed a positive effect in reducing weight loss and in maintaining ascorbic acid and carotenoid content. The application of thyme and savory essential oil vapors represents a promising tool for reducing postharvest losses and preserving the quality of peaches and nectarines., Competing Interests: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Published
2018
Full Text
View/download PDF

49. Abundance, genetic diversity and sensitivity to demethylation inhibitor fungicides of Aspergillus fumigatus isolates from organic substrates with special emphasis on compost.

Author

Santoro K, Matić S, Gisi U, Spadaro D, Pugliese M, and Gullino ML

Subjects
Antifungal Agents chemistry, Aspergillus fumigatus classification, Aspergillus fumigatus isolation & purification, Composting, Demethylation, Drug Resistance, Fungal, Fungal Proteins genetics, Fungal Proteins metabolism, Genetic Variation, Grassland, Antifungal Agents pharmacology, Aspergillus fumigatus drug effects, Aspergillus fumigatus genetics, Soil Microbiology
Abstract

Background: Aspergillus fumigatus is a widespread fungus that colonizes dead organic substrates but it can also cause fatal human diseases. Aspergilloses are treated with demethylation inhibitor (DMI) fungicides; however, resistant isolates appeared recently in the medical and also environmental area. The present study aims at molecular characterizing and quantifying A. fumigatus in major environmental habitats and determining its sensitivity to medical and agricultural DMI fungicides., Results: A. fumigatus was isolated only rarely from soil and meadow/forest organic matter but high concentrations (10 3 to 10 7  cfu/g) were detected in substrates subjected to elevated temperatures, such as compost and silage. High genetic diversity of A. fumigatus from compost was found based on SSR markers, distinguishing among fungal isolates even when coming from the same substrate sample, while subclustering was observed based on mutations in cyp51A gene. Several cyp51A amino acid substitutions were found in 15 isolates, although all isolates were fully sensitive to the tested DMI fungicides, with exception of one isolate in combination with one fungicide., Conclusion: This study suggests that the tested A. fumigatus isolates collected in Italy, Spain and Hungary from the fungus' major living habitats (compost) and commercial growing substrates are not potential carriers for DMI resistance in the environment. © 2017 Society of Chemical Industry., (© 2017 Society of Chemical Industry.)

Published
2017
Full Text
View/download PDF

50. Immunodetection of 17β-estradiol in serum at ppt level by microcantilever resonators.

Author

Ricciardi C, Ferrante I, Castagna R, Frascella F, Marasso SL, Santoro K, Gili M, Pitardi D, Pezzolato M, and Bozzetta E

Subjects
Equipment Design, Equipment Failure Analysis, Reproducibility of Results, Sensitivity and Specificity, Biosensing Techniques instrumentation, Estradiol blood, Immunoassay instrumentation, Micro-Electrical-Mechanical Systems instrumentation, Microchemistry instrumentation
Abstract

To date control strategies in detecting anabolic agents for promoting growth of food producing animals are mainly related to screening techniques based on immunochemical and physiochemical methods, whose major limit is represented by relative low analytical sensitivity. As a consequence, consumers are currently exposed to molecules with potential carcinogenic effects such as 17β-estradiol, the most powerful substance with estrogenic effect. Therefore, high analytical sensitivity screening and confirmatory methods are required, coupling easiness of use and efficiency. We here report on the immunodetection of 17β-estradiol in serum by antibody-immobilized microcantilever resonators, an innovative biosensing platform able to quantify an adsorbed target mass (such as cells, nucleic acids, biomolecules, etc.) thanks to a shift in resonance frequency. Our tool based on microcantilever resonator arrays has shown to be capable of discriminating treated and untreated animals, showing the ability of detecting traces of 17β-estradiol in serum at concentrations lower than the present accepted physiological serum concentration threshold value (40 ppt) and commercial ELISA tests (25 ppt). The method exhibits a limit of detection of 20 ppt and a limited cross-reactivity with high concentrations (10 ppb) of similar molecules (testosterone)., (Copyright © 2012 Elsevier B.V. All rights reserved.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results